Beta thalassemia is a blood disorder that affects the production of hemoglobin. Hemoglobin is the iron-rich protein in your ...

There are two main types of thalassemia: alpha and beta thalassemia, each with various subtypes. The severity of symptoms ...

It’s been almost a year since the Food and Drug Administration approved the first genetic treatments for sickle cell disease.

Considering taking supplements to treat beta thalassemia? Below is a list of common natural remedies used to treat or reduce the symptoms of beta thalassemia. Follow the links to read common uses ...

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $29.9 billion by 2032, ...

Beta-thalassemia is a rare blood disorder caused by a genetic defect in hemoglobin. Several manufacturers are developing novel treatments for the disease, including Vertex, which has partnered ...

For those with $200 to spare that isn't being saved for emergencies, let's consider two healthcare stocks within that budget ...

The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.

CRISPR Therapeutics' first therapy is called Casgevy. It treats sickle cell disease (SCD) and beta thalassemia, both rare ...

Having said that, it is an excellent introductory indication that may help hematologists decide whether or not to use it for sickle cell or beta thalassemia patients in the future. Expanding ...

He also believes there’s still too few of the therapies on the market to draw any sweeping conclusions on reasons for their ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...